Gene mutation and drug resistance of M. tuberculosis in the patients followed up in the city of Moscow
| Autor: | M. A. Krasnova, E. M. Belilovsky, S. E. Borisov, A. A. Khakhalina, Yu. D. Mikhaylova, E. Yu. Nosova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Туберкулез и болезни лёгких, Vol 97, Iss 12, Pp 34-44 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2075-1230 2542-1506 |
| DOI: | 10.21292/2075-1230-2019-97-12-34-44 |
| Popis: | The article describes a retrospective study of the results of microbiological and molecular genetic tests of 685 M. tuberculosis cultures isolated from 685 adult tuberculosis patients registered for dispensary follow-up in Moscow in 2014.The following was identified during the study: phenotypic drug resistance (FDR) of MTB to rifampicin, isoniazid, fluoroquinolones, kanamycin, amikacin, and capreomycin in groups of patients with different treatment history; the frequency of FDR to the above anti-tuberculosis drugs in strains with mutations being drug resistance markers; the frequency of various mutations in case of FDR of mycobacteria in the patients from different groups; the relationship of FDR or the presence of a particular mutation with various characteristics of the patients and their treatment history.The history of previous treatment was determined as statistical significance to provide the greatest influence on the spread of drug resistant MTB: patients undergoing repeated treatment had FDR more often and also a much more pronounced variety of mutations being markers of FDR to certain anti-tuberculosis drugs.The results of the study showed that the detection of genetic mutations in MBT associated with FDR was a reliable tool for predicting phenotypic resistance and should be used as the main method for selecting anti-tuberculosis drugs when compiling the etiotropic therapy regimen. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|